US researchers have identified MK 1775 as a possible molecule that could be used in the treatment of sarcomas, especially the type affecting children. The molecule inhibits Wee1, a nuclear kinase that regulates cell size and initiates cell division.
According to Soner Altiok, M.D., Ph.D. of Moffitt Cancer Center in Tampa, Floridaa, sarcomas are rare forms of cancers and are comprised of more than 70 types. Approximately 10 percent of children with cancer are diagnosed with sarcomas, compared to eight percent of young adults and one percent of adults. While chemotherapy and radiation play a role in treating some sarcoma patients, escalations of treatment are unlikely to be tolerable, nor will they prolong survival, said the researchers.
Rhabdomyosarcoma
Rhabdomyosarcoma is a rare type of cancer affecting the striated muscles. It mostly occurs in children.
Advertisement
"There is a great need for new agents to treat sarcomas and improve patient outcomes," said Altiok. "Toxicity from radiation and chemotherapy is high and response rates for patients with sarcomas are modest, with improvement and survival negligible."
Sarcomas are cancers that result from transformed cells in one of a number of tissues that develop from embryonic mesoderm. Sarcomas include tumors of bone, cartilage, fat, muscle, vascular and hematopoetic tissues. Sarcomas are different from carcinomas that originate in epithelial cells and result in more common cancers, such as breast, colon and lung cancers.
![Molecular Targets To Treat Childhood Muscle Cancer]( "Molecular Targets To Treat Childhood Muscle Cancer")
US scientists believe molecular targets to treat childhood muscle cancer could be on the anvil with the discovery of its cell of origin.
Researchers from Moffitt's Experimental Therapeutics Program and the Sarcoma Program collaborated in testing MK1775′s ability to inhibit Wee1. It is known to play a role in determining the time-point at which mitosis (cell division) begins. Loss of Wee1 can produce smaller than normal daughter cells. The researchers hypothesized that inhibition of Wee1 could also induce apoptosis, or programmed cell death in sarcoma tumors.
"Inhibition of the pathways critical to tumor cell survival by molecularly targeted therapy represents an opportunity to reverse the biological basis of tumor formation," explained Altiok. "We found that MK1775 treatment induces apoptopic cell death in four sarcoma cell lines at clinically relevant doses."
To further prove that inhibition of Wee1 by MK1775 leads to mitotic cell death in sarcomas cells, the researchers performed additional studies, including studies on sarcomas related to mutations, such as with the p53 gene. They also showed that MK1775 was an active inhibitor of Wee1 regardless of the p53 mutation status of the tumors in the cell lines tested.
"The cytotoxic effect of Wee1 inhibition on sarcoma cells appears to be independent of p53 mutation status following our testing sarcoma cell lines with different p53 mutations," he said. "All of them were highly sensitive to MK1775, suggesting that Wee1 inhibition may represent a novel approach in the treatment of sarcomas."
The researchers concluded that their laboratory tests on sarcoma cell lines suggest that MK1775 is effective as a monotherapy even in the cell lines that include p53 wild, p53 null and p53 mutant statuses.
Other studies have shown that MK1775 is a well-tolerated drug. No toxicity dose limit has been established, making MK 1775 a potential therapeutic agent for treating both adult and pediatric sarcoma patients.
"Our data has shown that MK1775 treatment causes cell death suggesting 'mitotic catastrophe,' a type of cell death that occurs during cell mitosis," concluded Altiok.
The findings are published in Molecular Cancer Therapeutics.
Source: Medindia
Molecular Targets To Treat Childhood Muscle Cancer
US scientists believe molecular targets to treat childhood muscle cancer could be on the anvil with the discovery of its cell of origin.
Advertisement
Researchers from Moffitt's Experimental Therapeutics Program and the Sarcoma Program collaborated in testing MK1775′s ability to inhibit Wee1. It is known to play a role in determining the time-point at which mitosis (cell division) begins. Loss of Wee1 can produce smaller than normal daughter cells. The researchers hypothesized that inhibition of Wee1 could also induce apoptosis, or programmed cell death in sarcoma tumors.
"Inhibition of the pathways critical to tumor cell survival by molecularly targeted therapy represents an opportunity to reverse the biological basis of tumor formation," explained Altiok. "We found that MK1775 treatment induces apoptopic cell death in four sarcoma cell lines at clinically relevant doses."
To further prove that inhibition of Wee1 by MK1775 leads to mitotic cell death in sarcomas cells, the researchers performed additional studies, including studies on sarcomas related to mutations, such as with the p53 gene. They also showed that MK1775 was an active inhibitor of Wee1 regardless of the p53 mutation status of the tumors in the cell lines tested.
"The cytotoxic effect of Wee1 inhibition on sarcoma cells appears to be independent of p53 mutation status following our testing sarcoma cell lines with different p53 mutations," he said. "All of them were highly sensitive to MK1775, suggesting that Wee1 inhibition may represent a novel approach in the treatment of sarcomas."
The researchers concluded that their laboratory tests on sarcoma cell lines suggest that MK1775 is effective as a monotherapy even in the cell lines that include p53 wild, p53 null and p53 mutant statuses.
Other studies have shown that MK1775 is a well-tolerated drug. No toxicity dose limit has been established, making MK 1775 a potential therapeutic agent for treating both adult and pediatric sarcoma patients.
"Our data has shown that MK1775 treatment causes cell death suggesting 'mitotic catastrophe,' a type of cell death that occurs during cell mitosis," concluded Altiok.
The findings are published in Molecular Cancer Therapeutics.
Source: Medindia
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
Chronotherapy (the sleep-wake cycle) is observed as a valuable alternative treatment in cancer diagnosis and treatment.
A nanoengineering platform targets neutrophils, the white blood cells without killing pancreatic cancer cells paving the way for effective treatments.
The survival rates between lobectomy and wedge resection surgical procedures were found to be the same among lung cancer patients.
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.